ERAP1,2 in Recalcitrant Warts

Benha University200 enrolled

Overview

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Warts

Interventions

endoplasmic reticulum Aminopeptidase 1 and 2DIAGNOSTIC_TEST

endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISADIAGNOSTIC_TEST

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: • Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin. Exclusion Criteria: * Patients with genital warts * Patients on systemic steroids or other immunosuppressive treatments * Immunocompromised individuals * Patients suffering from chronic systemic diseases * Pregnant women

Locations (1)

faculty of medicine Benha University

Banhā, Qalyubia Governorate, Egypt

Outcomes

Primary Outcomes

SERUM LEVELS OF endoplasmic reticulum aminopeptidase 1 and 2

using specific Commercial human ELISA kits

Time frame: ONE YEAR

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.